Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis - PubMed (original) (raw)

doi: 10.1155/2016/1459790. Epub 2016 Aug 29.

Sainan Li 2, Jingjing Li 2, Jianrong Wang 1, Rong Zhang 1, Yuqing Zhou 3, Qin Yin 3, Yuanyuan Zheng 2, Fan Wang 2, Yujing Xia 2, Kan Chen 2, Tong Liu 2, Jie Lu 2, Yingqun Zhou 2, Chuanyong Guo 2

Affiliations

Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis

Wenxia Lu et al. Gastroenterol Res Pract. 2016.

Abstract

A meta-analysis was conducted to assess the effect of omega-3 fatty acid supplementation (n-3 PUFAs) in lowering liver fat, liver enzyme (alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) levels), and blood lipids (triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL), and low density lipoprotein (LDL)) in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). Methods. MEDLINE/PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, CINAHL, Science Citation Index (ISI Web of Science), Chinese Biomedical Literature Database (CBM), and Chinese National Knowledge Infrastructure (CNKI) were searched for relevant randomized controlled trials on the effects of n-3 polyunsaturated fatty acids (PUFAs) in patients with NAFLD from inception to May 2015. Ten studies were included in this meta-analysis. Results. 577 cases of NAFLD/NASH in ten randomized controlled trials (RCTs) were included. The results of the meta-analysis showed that benefit changes in liver fat favored PUFA treatment, and it was also beneficial for GGT, but it was not significant on ALT, AST, TC, and LDL. Conclusions. In this meta-analysis, omega-3 PUFAs improved liver fat, GGT, TG, and HDL in patients with NAFLD/NASH. Therefore, n-3 PUFAs may be a new treatment option for NAFLD.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Flow diagram of the studies included in the meta-analysis.

Figure 2

Figure 2

Effects of n-3 PUFAs versus control in liver fat in patients with NAFLD.

Figure 3

Figure 3

Effects of n-3 PUFAs versus control on ALT in patients with NAFLD.

Figure 4

Figure 4

Effects of n-3 PUFAs versus control on AST in patients with NAFLD.

Figure 5

Figure 5

Effects of n-3 PUFAs versus control on GGT in patients with NAFLD.

Figure 6

Figure 6

Effects of n-3 PUFAs versus control on HDL in patients with NAFLD.

Figure 7

Figure 7

Effects of n-3 PUFAs versus control on LDL in patients with NAFLD.

Figure 8

Figure 8

Effects of n-3 PUFAs versus control on TC in patients with NAFLD.

Figure 9

Figure 9

Effects of n-3 PUFAs versus control on TG in patients with NAFLD.

Figure 10

Figure 10

Funnel plots for the meta-analysis.

References

    1. Angulo P. Nonalcoholic fatty liver disease. The New England Journal of Medicine. 2002;346(16):1221–1231. doi: 10.1056/nejmra011775. - DOI - PubMed
    1. Zhu F.-S., Liu S., Chen X.-M., Huang Z.-G., Zhang D.-W. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World Journal of Gastroenterology. 2008;14(41):6395–6400. doi: 10.3748/wjg.14.6395. - DOI - PMC - PubMed
    1. Pagadala M. R., McCullough A. J. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clinics in Liver Disease. 2012;16(3):487–504. doi: 10.1016/j.cld.2012.05.006. - DOI - PMC - PubMed
    1. Lizardi-Cervera J., Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease. Annals of Hepatology. 2009;8(1):S40–S43. - PubMed
    1. Targher G., Day C. P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. The New England Journal of Medicine. 2010;363(14):1341–1350. doi: 10.1056/nejmra0912063. - DOI - PubMed

LinkOut - more resources